In August 2026, the American Society of Hematology issued updated clinical practice guidelines for immune thrombocytopenia, recommending that newly diagnosed patients receive combination therapy featuring corticosteroids alongside thrombopoietin receptor agonists or rituximab rather than steroids alone.
Immune thrombocytopenia is a rare blood disorder characterized by autoimmune destruction of platelets, cell fragments essential for normal blood clotting. The condition manifests clinically as petechiae, purpura, and an elevated risk of hemorrhage. Historically, frontline management relied almost exclusively on high-dose corticosteroids to blunt immune-mediated clearance. However, long-term steroid exposure frequently precipitates adverse metabolic and musculoskeletal sequelae, driving hematologists to seek more targeted interventions.
Combining Targeted Drugs with Steroids Helps Patients Achieve Stable Platelet Counts
- Beyond Steroids: Newly updated guidelines advise doctors to combine initial steroid treatments with targeted drugs to help patients achieve stable platelet counts faster.
- Mechanism Focus: Second-line options now include specific enzyme inhibitors and biological therapies that prevent immune cells from destroying circulating platelets.
- Personalized Care: Treatment selection heavily weighs patient lifestyle, prior treatment failures, and comorbid health conditions rather than a one-size-fits-all approach.
Evolving First-Line Combination Protocols
Clinical data underpinning the new recommendations indicate that concurrent administration of corticosteroids with thrombopoietin receptor agonists or rituximab achieves superior sustained platelet recovery compared to monotherapy. James Bussel, MD, a hematologist at Weill Cornell Medicine in New York City, notes that combining treatments early offers an effective path forward for patients.
Thrombopoietin receptor agonists function by mimicking endogenous thrombopoietin, a hormone regulating megakaryocyte proliferation and platelet synthesis in the bone marrow. Available agents in this class include daily oral formulations such as eltrombopag, marketed as Promacta, and avatrombopag, marketed as Doptelet, alongside romiplostim, administered as a weekly subcutaneous injection. These therapies rapidly elevate platelet counts within approximately two weeks without inducing generalized immunosuppression.
Alternatively, first-line or second-line management frequently incorporates rituximab, a monoclonal antibody directed against the CD20 surface antigen expressed on B-lymphocytes. Administered as a course of four weekly intravenous infusions, rituximab depletes antibody-producing B-cells. Cindy Neunert, MD, a hematologist at Columbia University Irving Medical Center, describes the intervention as a immunological reset that can yield long-term treatment-free remissions.
Fostamatinib Interrupts Intracellular Signaling Cascades Within Macrophages
Fostamatinib, a twice-daily oral spleen tyrosine kinase inhibitor, works by interrupting intracellular signaling cascades within macrophages, thereby preventing the phagocytosis of antibody-opsonized platelets. Approximately half of patients receiving fostamatinib achieve a durable response at six months.
Rilzabrutinib, a Bruton’s tyrosine kinase inhibitor, disrupts signaling pathways spanning B-cells, platelets, and macrophages to simultaneously curtail autoantibody production and platelet clearance.
Mycophenolate mofetil acts as an immunosuppressant suppressing both B-cell and T-cell proliferation. While roughly 65 percent of patients achieve lasting responses at six months in clinical cohorts, gastrointestinal adverse effects frequently impact patient quality of life. Meanwhile, surgical splenectomy remains a viable second-line strategy for patients requiring rapid platelet stabilization or wishing to avoid chronic pharmacotherapy. Because the spleen serves as the primary site for both autoantibody synthesis and platelet sequestration, laparoscopic splenectomy yields high response rates, though it carries a lifelong, albeit low, risk of severe sepsis and thromboembolism.
| Therapeutic Class | Representative Agents | Route of Administration | Primary Mechanism |
|---|---|---|---|
| TPO-Receptor Agonists | Eltrombopag, Avatrombopag, Romiplostim | Oral daily or Subcutaneous weekly | Stimulates bone marrow megakaryocytes to increase platelet production |
| B-Cell Depletion | Rituximab | Intravenous infusion (weekly x 4) | Targets CD20+ B-cells to reduce autoantibody formation |
| SYK Inhibitors | Fostamatinib | Oral twice daily | Blocks macrophage signaling to prevent platelet phagocytosis |
| BTK Inhibitors | Rilzabrutinib | Oral twice daily | Inrupts BTK signaling in B-cells and macrophages |
Patients with Severe Infections Must Avoid Immunosuppressive Agents Until Cleared
Patients with active, severe systemic infections must exercise caution or avoid broad immunosuppressive agents like rituximab and mycophenolate mofetil until infections are fully cleared. Splenectomy is generally contraindicated in individuals unable to tolerate minimally invasive surgical procedures or those lacking proper immunization status against encapsulated organisms such as Streptococcus pneumoniae. Individuals experiencing sudden, unexplained bruising, petechial rashes, mucosal bleeding, or spontaneous epistaxis should immediately seek professional medical evaluation to assess platelet nadir levels and rule out acute hemorrhagic complications.
Personalized Shared Decision-Making
Selecting an optimal therapeutic pathway requires evaluating individual patient profiles, occupational risks, financial constraints, and personal preferences regarding chronic medication adherence versus surgical intervention. As Dr. Neunert emphasizes, clinical decision-making centers entirely on understanding prior treatment responses, existing comorbidities, and overall health characteristics to tailor an effective, sustainable management plan.
References
- American Society of Hematology. Guidelines for Immune Thrombocytopenia Management. Published August 2026.
